銀城國際控股(01902.HK):預計將根據交換要約發行9596.5萬美元新票據
格隆匯3月4日丨銀城國際控股(01902.HK)發佈公吿,有關公司2022年2月25日關於公司現有票據(股份代號:40619)交換要約的公吿。交換要約已於2022年3月3日倫敦時間下午4時屆滿。公司特此通知合資格持有人,截至交換屆滿期限,本金總額為9596.5萬美元的現有票據(約佔現有票據本金總額的58.16%)已根據交換要約進行了有效的交換提交。
公司已決定接受本金總額為9596.5萬美元的現有票據進行交換。對於有效進行交換提交併被接受的現有票據,在交換要約的先決條件得到滿足或豁免的情況下,公司預計將根據交換要約發行本金總額為9596.5萬美元的新票據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.